(Q37968506)

English

Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature

scientific article published on 15 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

based on heuristic

inferred from title

5

object named as

Elias Anaissie

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Jameel Muzaffar

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Lakshmikanth Katragadda

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sajjad Haider

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Ali Javed

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Saad Usmani

6

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

15 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

102-106

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Acquired von Willebrand syndrome: an update

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Rituximab for the treatment of acquired antibodies to factor VIII.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0968-7

21 January 2018

Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma presenting with acquired factor VIII inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired hemophilia in patients with hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22170228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-011-0968-7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37968506&oldid=2201122589"